[Cytokine antagonists and endothelin antagonists for therapy of heart failure].
Matsumori
Akira
A
D000804:Angiotensin II / Q000502:physiology; D000818:Animals; D000911:Antibodies, Monoclonal / Q000494:pharmacology / Q000627:therapeutic use*; D000077300:Bosentan; D002986:Clinical Trials as Topic; D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000502:physiology; D016232:Endothelins / Q000037:antagonists & inhibitors* / Q000502:physiology; D000068800:Etanercept; D015316:Genetic Therapy; D006333:Heart Failure / Q000188:drug therapy* / Q000209:etiology; D006801:Humans; D007074:Immunoglobulin G / Q000494:pharmacology / Q000627:therapeutic use*; D000069285:Infliximab; D016753:Interleukin-10 / Q000235:genetics / Q000627:therapeutic use; D008407:Mast Cells; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000502:physiology; D019009:Proto-Oncogene Proteins c-kit; D011724:Pyridazines / Q000494:pharmacology / Q000627:therapeutic use*; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D013449:Sulfonamides / Q000494:pharmacology / Q000627:therapeutic use*
D000911:Antibodies, Monoclonal; D016207:Cytokines; D016232:Endothelins; D007074:Immunoglobulin G; D016328:NF-kappa B; D011724:Pyridazines; D018124:Receptors, Tumor Necrosis Factor; D013449:Sulfonamides; D000804:Angiotensin II; D016753:Interleukin-10; C041648:pimobendan; D000069285:Infliximab; D019009:Proto-Oncogene Proteins c-kit; D000068800:Etanercept; D000077300:Bosentan